TG Therapeutics (TGTX) Set to Announce Quarterly Earnings on Monday
Nov 2, 2024
Therapeutics Invest Information
Atossa Therapeutics Receives Buy Rating from HC Wainwright
Oct 31, 2024
Abeona Therapeutics Receives Buy Rating from HC Wainwright
Oct 31, 2024
Enliven Therapeutics Reports Encouraging Phase 1 Results for ELVN-001 in Chronic Myeloid Leukemia Treatment
Sep 29, 2024
Pliant Therapeutics Showcases Promising Bexotegrast Program Data at ERS International Congress 2024
Sep 10, 2024
Unicycive Therapeutics Announces Presentation at H.C. Wainwright Global Investment Conference
Sep 6, 2024
Addex Therapeutics Faces Setback as Partner Halts ADX71149 Development in Epilepsy
Jul 22, 2024
Gain Therapeutics Presents Key Data on GT-02287 at FENS Forum 2024
Jun 27, 2024
Anavex Life Sciences Bolsters Leadership to Enhance Global Healthcare Delivery
May 23, 2024
Cognition Therapeutics Announces Completion of Patient Enrollment for CT1812 Phase 2 Study in Dementia with Lewy Bodies
Apr 29, 2024
SpringWorks Therapeutics Announces Presentation at J.P. Morgan Healthcare Conference
Dec 21, 2023
Xilio Therapeutics Commences Phase 1 Trial for XTX101 in Combination Therapy for MSS CRC
Dec 7, 2023
Rosen Law Firm Urges Brainstorm Cell Therapeutics Inc. Investors with Losses to Act Before Deadline
Nov 12, 2023
TG Therapeutics TGTX Upgraded to 'Buy' by StockNews.com Amid Positive Analyst Sentiment
Nov 12, 2023
Intellia Therapeutics Surpasses Q3 Earnings Expectations and Announces Progress in Gene-Editing Pipeline
Nov 11, 2023
Pasithea Therapeutics Advances ALS Treatment with New Lead Candidate PAS-003 Targeting α5β1 Integrin
Nov 9, 2023
Catalyst Pharmaceuticals Delivers Mixed Q3 Results While Raising 2023 Outlook
Nov 9, 2023